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Abstract
Purpose There is a direct association between salt intake and blood pressure (BP), one of the main risk factors for CVDs. 
However, yet there has been a debate that how strong is this association in people with and without hypertension. This study 
was conducted to evaluate the magnitude of the association between salt intake and BP in hypertensive and normotensive 
population among a nationally representative population.
Methods The study was conducted on a nationally representative sample of 18,635 Iranian adults aged 25 years and older 
who participated in the STEPS survey 2016 and provided urine sample. Salt intake was estimated through spot urine sample 
and Tanaka equation. Multiple linear regression model in survey data analysis was used to assess the independent effect of 
salt intake on BP.
Results After adjusting for covariates, there was a significant association between salt intake and SBP in hypertensive 
(p < 0.001) and normotensive people (p < 0.001). In hypertensive people, with 1 g of increase in salt intake, the SBP and DBP 
increased 0.37 mmHg and 0.07 mmHg, respectively. Whereas in normotensive people, with 1 g of increase in salt intake, 
the SBP and DBP increased 0.26 mmHg and 0.05 mmHg, respectively. Moreover, there was a significant trend toward an 
increase of SBP across salt intake quartiles in both hypertensive (p < 0.001) and normotensive people (p = 0.002), though 
the slope was steeper in hypertensive than in normotensive people.
Conclusions The present study demonstrated that salt intake significantly increased SBP in both hypertensive and normoten-
sive people, though the magnitude of this increase was greater in hypertensive people as compared with normotensive people.
Keywords Salt · Blood pressure · Hypertensive · Normotensive · Iran
Introduction
Excess salt intake is associated with the development of sev-
eral non-communicable diseases, including cardiovascular 
diseases (CVDs), the leading cause of death [1] and stomach 
cancer, the third leading cause of cancer death worldwide [2, 
3]. Diet high in sodium was responsible for 20.32% hyper-
tensive heart disease death, 13.47% stroke death, 11.58% 
ischemic heart diseases death, and 9.83% stomach cancer 
death worldwide [4]. Excess salt intake exerts its detrimental 
effect directly or through increasing the blood pressure (BP) 
[3].
Hypertension (HTN) is one of the main risk factors for 
CVDs. It has been estimated that HTN is responsible for 
more than half of deaths from stroke and coronary heart dis-
ease in adults worldwide [4]. The role of excess salt intake 
in increasing BP has been confirmed in the previous epide-
miological and clinical studies [5]. However, debates exist 
over the relationship of salt intake and its effect on BP in 
the general population [6, 7]. These debates focus on find-
ings achieved from some clinical trials with the controlled 
circumstance that it might not be simply generalized to gen-
eral populations. In this setting, a high-quality observational 
study has revealed only a weak association between sodium 
intake and BP in the general population [8].
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It was indicated that salt restriction interventions had a 
lower effect on BP in normotensive people, compared to 
hypertensive people [4]. In addition, the extreme salt reduc-
tion could lead to unfavorable effect in the general popu-
lation [9]. Therefore, knowing the differences between the 
association of salt intake and BP in both hypertensive and 
normotensive people could assist health policymakers to 
consider this difference in the salt reduction policies. To 
date, there are limited data on the relationship between salt 
intake and BP in hypertensive and normotensive people [10]. 
Therefore, the objective of the present study was to evaluate 
the magnitude of the association between salt intake and BP 
in hypertensive and normotensive people.
Materials and methods
Design and sample
This study was conducted in the framework of STEPwise 
approach in surveillance of non-communicable diseases 
(STEPS) survey in Iran, during 2016. A detailed descrip-
tion of the study design is provided in the study protocol of 
the study [11]. In brief, the study was a national large-scale 
cross-sectional survey in that individuals aged 18 years old 
and above were recruited from urban and rural areas of all 
provinces of Iran (except Qom province) using stratified ran-
dom cluster sampling. The STEPS consists of three steps, 
including (1) questionnaire-based assessment, (2) physical 
measurement, and (3) biochemical measurements [12]. In 
Iran, STEPS 2016 among the 31,050 recruited participants, 
30,541 participants completed the first step (questionnaire) 
and 30,042 participants completed the second step (physical 
measurement). The third step (biochemical measurement) 
was merely performed in participants aged 25 years and 
above. A total of 2803 out of 30,541 participants were in 
the age category of 18–25 years and did not invite to par-
ticipate in the third step. Therefore, 27,738 subjects were 
eligible and invited for biochemical measurement; how-
ever, 19,778 subjects participated in the third step (response 
rate = 71.3%). The participants who did not take part in the 
third step (7960 subjects) were defined as nonresponsive. We 
considered non-response bias weight in our survey analy-
sis. Among the participants who completed the biochemi-
cal measurements, 18,635 participants had a proper urine 
sodium measurement and were included in this study [11]. 
The remaining (1143 subjects) were considered as missing 
data.
Measures
Salt intake and BP were used as independent and depend-
ent factors in this study. Some other factors were used as 
covariates in relationship between salt intake and BP, 
including: age, sex, educational level, marital status, local 
residence, tobacco use, alcohol consumption, fruit intake, 
vegetable intake, weight status, low physical activity, wealth 
index, province, having diabetes, total cholesterol, hyperten-
sion awareness, and treatment history for hypertension.
Measurement and definition of dependent, 
independent and covariates factors
BP (mmHg) was measured thrice using a digital sphyg-
momanometer (Beurer BM20, Beurer GmbH, Ulm, Ger-
many) after a rest of 15 min in sitting position. Hyper-
tension was defined (definition 1) as having any of the 
following items: (1) BP ≥ 130/80 mmHg [13]; (2) use of 
anti-hypertensive medications; (3) self-report of hyperten-
sion. We also defined (definition 2) hypertension based on 
same criteria except that BP ≥ 140/90 mmHg [14] instead 
of BP ≥ 130/80 mmHg and we analyzed the association of 
salt intake and BP according to these two definitions. To 
estimate salt intake, urinary spot samples (collected in the 
morning) were taken in STEPS survey. The Tanaka equation 
[15] was used to estimate 24 h urinary sodium. Then, the 
obtained values were multiplied by 2.54 and divided by 1000 
to get salt intake (g/day) for each person [16].
The data of age, sex, educational level, marital status, 
local residence, tobacco use, alcohol consumption, fruit 
intake, vegetable intake, weight status, low physical activity, 
assets items, hypertension awareness and treatment history 
for hypertension were obtained by trained interviewers. BP, 
height, and weight measurements were performed by trained 
health personnel. Total cholesterol and fasting blood sugar 
were measured from collected blood samples. Educational 
level was categorized into three categories, including less 
than high-school graduate, high-school graduate, and some 
college or more. Use of tobacco and alcohol consumption 
was defined as current user, former user, and never user. 
Consumption of fruit was categorized as more than 2 serv-
ings/day; 2 servings/day; 1 serving/day; less than 1 serv-
ing/day; or no fruit intake. Consumption of vegetables was 
categorized as more than 5 servings/day; 4–5 servings/
day; 3 servings/day; less than 3 servings/day; or no veg-
etable intake. Total cholesterol was divided into two cat-
egories, including < 200 mg/dl and ≥ 200 mg/dl. Diabetes 
was defined as having any of the following criteria: fasting 
blood sugar (FBS) ≥ 126 mg/dl, intake of anti-diabetic medi-
cations, or self-reporting of diabetes. Physical activity was 
assessed by the second version of Global Physical Activity 
Questionnaire [17]. Easy-to-collect data on a household’s 
ownership (assets items) and principal component analysis 
were used to calculate the wealth index. Wealth index was 
used as a proxy to determine the household economic status 
of the study population.
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Statistical analysis
The statistical analysis of this study was conducted on 
18,631 individuals aged 25 years and older; four of 18,635 
individuals did not have blood pressure measurement. For 
considering the cluster sampling effect, all the analyses were 
performed using survey analysis. Multiple linear regres-
sion model in survey data analysis was used to assess the 
independent effect of salt intake on BP among hypertensive 
and normotensive individuals after adjusting for covari-
ates. The study population was divided into four categories 
(Q1–Q4) according to quartiles of salt intake. Quartiles 1 
through 4 were ≤ 7.89, > 7.89–9.47 ≥ , > 9.47–11.09 ≥ , > 11
.09 g/day. We used the lowest quartile (Q1) as the reference 
group in some analyses. The results presented in the text 
are related to the value of the definition 1 of hypertension 
(BP ≥ 130/80 mmHg) and the results of the second defini-
tion of hypertension are provided in the Tables 4, 5, 6. The 
results are reported as mean and standard deviation (SD). 
All the statistical analyses were performed using STATA 
software version 14 and p < 0.05 was considered as statisti-
cally significant.
Ethical considerations
The Ethical Committee of National Institute for Medical 
Research Development (NIMAD) approved the study (Ethi-
cal code: IR.NIMAD.REC.1394.032). All the participants 
were aware of the study’s objectives and methods and gave 
a written informed consent form prior initiation of the study.
Results
Characteristics of the study population
The characteristics of the study population are presented 
in Table 1. The mean age of the study population was 46.9 
(14.1) years and 52.1% of them were female (Table 1). The 
mean age of the hypertensive and normotensive population 
was 52.0 (14.5) and 41.6 (12.6) years, respectively. Mean 
salt intake was 9.7 (2.4) g/day in hypertensive population 
and 9.3 (2.3) g/day in a normotensive population. The mean 
SBP of the study population was 137.6 (18.2) in hyperten-
sive population and 113.0 (8.9) mmHg in a normotensive 
population. The mean DBP of the study population was 84.1 
(10.3) in hypertensive population and 69.8 (6.6) mmHg in a 
normotensive population. Characteristics of the study popu-
lation across the quartiles of salt intake and hypertension 
status are shown in Tables 2, 3.
Association of salt intake and BP in hypertensive 
population
The results of the unadjusted and adjusted association 
between salt intake and BP are demonstrated in Table 4. 
The significant associations were observed between salt 
intake and SBP in the unadjusted (β 0.43; 95% CI 0.25–0.60; 
p < 0.001) and all the adjusted models (p < 0.05) (Table 4). 
Regarding the DBP, a significant association was observed 
in the unadjusted model (β 0.15; 95% CI 0.05–0.25; 
p < 0.01); however, after adjusting for all the covariates, 
the significance of the association was lost (β 0.07; 95% 
CI 0.05–0.18; p = 0.256). As presented in Table 5, in the 
adjusted models, comparison of each salt quartile with the 
first quartile resulted in an increase in most of SBP and 
DBP values; however, the increase was much higher in the 
fully adjusted models. In this setting, after adjusting for all 
covariates (model 4), we observed that participants who 
consumed > 11.09 g salt per day (quartile 4) had 3.81 (95% 
CI 2.00–5.61) mmHg SBP significantly higher than those 
who consumed ≤ 7.89 g/day (quartile 1) (Fig. 1). Moreover, 
it was observed that the values of SBP and DBP in each 
model were significantly different across quartiles (p < 0.05) 
(except models 3 and 4 in DBP).
Association of salt intake and BP in normotensive 
population
The association between salt intake and BP in normotensive 
population (BP < 130/80 mmHg and no use of anti-hyperten-
sive medications and no reporting of hypertension) is shown 
in Table 4. The salt intake was significantly associated with 
SBP in the unadjusted (β 0.41; 95% CI 0.31–0.50; p < 0.001) 
and all adjusted models (p < 0.05). Regarding the DBP, in 
the unadjusted model, there was a significant association 
between salt intake and DBP (β 0.17; 95% CI 0.10, 0.24; 
p < 0.001); while, in the full adjusted model, no signifi-
cant association was observed (β 0.05; 95% CI 0.03–0.13; 
p = 0.212).
As presented in Table 6, when the models were adjusted 
for covariates, comparison of each salt quartile with the first 
quartile resulted in an increase in most of SBP and DBP 
values. In this context, we observed that participants who 
consumed > 11.09 g salt per day (quartile 4) had 1.39 mmHg 
(95% CI 0.52–2.26) SBP significantly higher than those who 
consumed ≤ 7.89 g/day (quartile 1) in the fully adjusted 
model (p < 0.05) (Fig.  1). Also, when the models were 
adjusted for covariates, it was observed that the increased 
values of SBP and DBP in each model were significantly 
different across quartiles (except models 3 and 4 in DBP).
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Table 1  Characteristics of the study population in the salt study and the overall STEPS study
Characteristics Overall STEPS study (n = 30,541) Salt study (n = 18,631)
Normotensivea Hypertensiveb
Number of subjects, no./total no. (%) – 8073/18,631 (42.5) 10,558/18,631 (57.5)
Salt intake – 9.3 ± 2.3 9.7 ± 2.4
Age, years (SD) 46.9 ± 14.1 41.6 ± 12.6 52.0 ± 14.5
Female sex, no./total no. (%) 15,975/30,541 (52.1) 4386/8073 (55.4) 5575/10,558 (53.1)
Educational level, no./total no. (%)
 Less than high-school graduate 17,852/29,471 (60.0) 4832/7974 (58.2) 7591/10,285 (71.5)
  High-school graduate 6212/29,471 (22.1) 1654/7974 (22.6) 1549/10,285 (16.9)
  Some college or more 5407/29,471 (17.9) 1488/7974 (19.3) 1145/10,285 (11.7)
Marital status, no./total no. (% married) 23,114/29,929 (81.1) 6688/8041 (83.0) 8817/10,520 (83.7)
Local residence, no./total no. (% urban) 21,493/30,541 (78.2) 5238/8073 (69.3) 6873/10,558 (70.9)
Tobacco use, no./total no. (%)
 Never 23,656/29,987 (78.8) 6262/8051 (78.7) 8199/10,540 (78.5)
  Former 2115/29,987 (6.6) 543/8051 (6.3) 957/10,540 (8.6)
  Current 4216/29,987 (14.6) 1246/8051 (15.1) 1384/10,540 (12.8)
Alcohol consumption, no./total no. (%)
  Never drank 27,563/29,877 (92.2) 7311/8039 (91.5) 9815/10,526 (92.9)
  Former drinker 1155/29,877 (4.0) 388/8039 (4.5) 416/10,526 (4.2)
  Current drinker 1159/29,877 (3.8) 340/8039 (4.0) 295/10,526 (3.0)
Fruits intake, no./total no. (%)
  No intake 6524/29,939 (20.5) 1725/8030 (20.5) 2435/10,533 (21.7)
  < 1 serving 6027/29,939 (20.7) 1553/8030 (20.4) 2169/10,533 (21.0)
  1 serving 12,203/29, 939 (41.9) 3230/8030 (40.3) 4174/10,533 (40.4)
  2 serving 3841/29,939 (12.2) 1119/8030 (13.6) 1324/10,533 (12.4)
  > 2 serving 1344/29,939 (4.7) 403/8030 (5.2) 431/10,533 (4.4)
Vegetables intake, no./total no. (%)
  No intake 9978/29,993 (32.7) 2536/8052 (31.2) 3442/10,540 (32.6)
  < 3 serving 7291/29,993 (24.1) 2015/8052 (25.7) 2567/10,540 (24.1)
  3 serving 10,199/29,993 (34.5) 2809/8052 (34.5) 3610/10,540 (34.5)
  4–5 serving 1974/29,993 (6.7) 558/8052 (6.8) 709/10,540 (6.8)
  > 5 serving 551/29,993 (2.0) 134/8052 (1.8) 212/10,540 (2.1)
Weight status, no./total no. (%)
  Underweight 1176/29,124 (2.8) 412/8073 (4.8) 222/10,558 (1.9)
  Normal 10,676/29,124 (34.1) 3383/8073 (40.2) 2752/10,558 (26.1)
  Overweight 10,659/29,124 (38.5) 2863/8073 (36.8) 4288/10,558 (40.8)
  Obese 6613/29,124 (24.5) 1415/8073 (18.2) 3296/10,558 (31.3)
Low activity (%) 15,157/26,965 (58.5) 3828/7088 (55.3) 5329/9519 (57.1)
Wealth index, no./total no. (%)
  Poorest 5902/29,310 (18.3) 1556/7964 (18.4) 2326/10,438 (20.5)
  Poor 5864/29,310 (19.1) 1566/7964 (19.0) 2194/10,438 (20.9)
  Moderate 5863/29,310 (20.3) 1632/7964 (21.3) 2118/10,438 (20.5)
  Rich 5851/29,310 (21.6) 1629/7964 (20.6) 1960/10,438 (19.4)
  Richest 5830/29,310 (20.7) 1581/7964 (20.6) 1840/10,438 (18.8)
Diabetes, no./total no. (%) 2011/20,113 (10.9) 369/7962 (5.2) 1530/10,416 (15.1)
Total cholesterol (≥ 200 mg/dl), no./total no. (%) 3143/20,231 (16.0) 840/8007 (11.0) 2017/10,479 (19.3)
Hypertension awareness, no./total no. (%) 6296/15,933 (39.1) – 4480/10,557 (41.4)
Treatment history for hypertension, no. (%) 3230/14,380 (22.6) – 2310/9492 (23.9)
SBP, mmHg 126.7 (18.8) 113.0 (8.9) 137.6 (18.2)
DBP, mmHg 78.0 (11.3) 69.8 (6.6) 84.1 (10.3)
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Association of salt intake and BP in total population
After adjusting for all covariates, including salt intake and 
hypertension status interaction, we found that participants 
who were in the quartile 2, 3, and 4 had 0.52 mmHg (95% 
CI 0.43–1.47; p = 0.285), 0.87 mmHg (95% CI 0.18–1.92; 
p = 0.105), and 1.53 mmHg (95% CI 0.53–2.53; p = 0.003) 
SBP higher than those who were in quartile 1, respectively.
Furthermore, we observed that participants who were in 
the quartile 2, 3, and 4 had 0.36 mmHg (95% CI 0.29–1.02; 
p = 0.273), 0.17 mmHg (95% CI 0.48–0.83; p = 0.603), and 
0.80 mmHg (95% CI 0.13–1.47; p = 0.019) DBP higher than 
those who were in quartile 1, respectively.
Discussion
In this nationally representative study of Iranian adults, it 
was found that after adjusting for covariates, there was a 
significant positive association between salt intake and SBP 
in hypertensive and normotensive participants. On the con-
trary, no significant association was observed between salt 
intake and DBP in both groups.
The association of salt intake and BP was stronger in 
hypertensive than in normotensive people. For instance, in 
hypertensive people, after adjusting for all covariates, we 
observed that with 1 g of increase in salt intake, the SBP and 
DBP increased 0.37 mmHg and 0.07 mmHg, respectively. 
Whereas, in the normotensive people, with 1 g of increase 
in salt intake, the SBP and DBP increased 0.26 mmHg and 
0.05 mmHg, respectively. Therefore, the association of salt 
intake and systolic and diastolic BP in hypertensive people 
was more than 1.4 times higher than that in normotensive 
people. The same pattern was observed when the definition 
2 of hypertension was included in the analysis.
The findings of the present study are consistent with the 
findings of the Mente and colleagues’ study. Mente and 
colleagues used the population urban and rural epidemio-
logical (PURE) study’s data to find the association between 
the urinary sodium and potassium excretion and BP. The 
data of 102,216 adults from 18 countries were analyzed. 
They used urine specimen and Kawasaki equation to esti-
mate the 24 h urinary excretion of sodium. They indicated 
that estimated sodium excretion was more strongly asso-
ciated with increased BP in individuals with HTN than in 
those with normal BP. For instance, in hypertensive people, 
with 1 g of increase in sodium excretion, the SBP increased 
2.49  mmHg, while in normotensive people, the SBP 
increased 1.30 mmHg (p < 0.001) [10]. One of the possible 
reasons for the larger effect of salt intake on hypertensive 
individuals could be related to differences in salt sensitivity 
between hypertensive and normotensive people. Hyperten-
sive people have almost two times higher salt sensitivity than 
normotensive people [4, 18].
In this study, it was found that SBP and DBP were greater 
in the highest quartile of salt intake, when compared with 
the lowest quartile in both hypertensive and normotensive 
people. Similarly, in the PURE study, participants who had a 
higher sodium excretion had a greater change in systolic and 
diastolic BP than in participants who had a lower sodium 
excretion. In the PURE study, the sodium excretion was 
divided into three categories, < 3 g/day, 3–5 g/day, and > 5 g/
day. They observed that changes in SBP and DBP were posi-
tively greater in participants who had a sodium excretion at 
the level of > 5 g/day than participants who had a sodium 
excretion at the level of 3–5 g/day or less than 3 g/day [10].
The results of the present study are in contrary to the 
Sharma and colleagues’ study. They investigated the associa-
tion between dietary sodium and potassium intake and BP 
levels in 6985 US adults with no prior history of hyperten-
sion. Sharma and colleagues divided the sodium intake into 
four quartiles and assessed the association of sodium intake 
and elevated BP across them. After adjusting for covari-
ates, they observed that there was no significant association 
between sodium intake and risk of elevated BP [19]. There 
are several differences between the Sharma and colleagues’ 
study with our study. First, Sharma and colleagues calcu-
lated the odds ratio of BP (> 130/80 and > 140/90 mmHg) 
and salt intake. They did not analyze the odds ratio of SBP 
and DBP with salt intake autonomously. As shown in the 
Table 1  (continued)
Characteristics Overall STEPS study (n = 30,541) Salt study (n = 18,631)
Normotensivea Hypertensiveb
Stroke history in the last year, no./total no. (%) 215/29,980 (0.7) 21/8059 (0.2) 110/10,549 (1.0)
Myocardial infraction, no./total no. (%) 441/29,968 (1.7) 50/8058 (0.6) 254/10,550 (2.3)
Statin medication, no./total no. (%) 2259/29,980 (8.5) 285/8058 (3.5) 1296/10,545 (12.1)
Aspirin medication, no./total no. (%) 3133/29,957 (11.8) 434/8054 (5.4) 1784/10,541 (16.9)
SD standard deviation, SBP systolic blood pressure, DBP diastolic blood pressure
a BP < 130/80 mmHg and no use of anti-hypertensive medications and not having history of hypertension
b BP ≥ 130/80 mmHg or use of anti-hypertensive medications or self-report of hypertension
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Table 2  Baseline characteristics of  hypertensivea study population across quartiles of salt intake
BP blood pressure, SBP systolic blood pressure, DBP diastolic blood pressure
a BP ≥ 130/80 mmHg or use of anti-hypertensive medications or self-report of hypertension
Characteristics Salt intake (g/day) quartiles p value
≤ 7.89 > 7.89–9.47 ≥ > 9.47–11.09 ≥ > 11.09
Total population 2479 2540 2657 2882 –
Mean age, years (SD) 51.2 ± 14.9 51.7 ± 14.4 52.6 ± 14.3 52.5 ± 14.5 0.035
Gender (% female) 59.0 54.7 49.8 49.4 < 0.001
Educational level (%)
  Less than high-school graduate 68.7 68.1 71.7 76.8 < 0.001
  High-school graduate 18.4 19.2 15.9 14.3
  Some college or more 12.9 12.7 12.4 8.9
Marital status (% married) 80.2 83.4 85.8 85.2 < 0.001
Local residence (% urban) 71.6 73.4 70.1 68.8 0.005
Tobacco use (%)
  Never 77.4 78.3 78.7 79.6 < 0.001
  Former 7.3 8.2 8.7 10.1
  Current 15.3 13.5 12.6 10.3
Alcohol consumption (%)
  Never drank 92.6 92.8 93.0 93.0 0.843
  Former drinker 4.0 4.1 4.4 4.2
  Current drinker 3.4 3.1 2.6 2.8
Fruits intake (%)
  No intake 22.8 21.7 20.7 21.6 0.153
  < 1 serving 22.3 21.1 20.5 20.5
  1 serving 38.9 41.8 40.0 41.0
  2 serving 12.2 11.6 14.1 11.7
  > 2 serving 3.8 3.8 4.7 5.2
Vegetables intake (%)
  No intake 34.3 33.2 31.8 31.2 0.555
  < 3 serving 23.3 24.0 25.6 23.3
  3 serving 33.2 34.3 34.3 35.9
  4–5 serving 7.1 6.6 6.1 7.3
  > 5 serving 2.1 1.9 2.2 2.3
Weight status, no./total no. (%)
  Underweight 3.4 2.0 1.3 0.9 < 0.001
  Normal 30.1 27.3 27.2 20.2
  Overweight 40.5 40.9 41.5 40.1
  Obese 26.0 29.8 30.0 38.8
Low activity (%) 58.7 58.4 56.7 54.7 0.081
Wealth index (%)
  Poorest 18.8 19.5 20.3 23.0 0.017
  Poor 20.8 21.1 20.0 21.5
  Moderate 20.8 19.1 21.0 21.0
  Rich 19.9 19.7 20.2 18.1
  Richest 19.7 20.6 18.5 16.4
Diabetes (%) 14.2 15.4 14.7 16.1 0.437
Total cholesterol (≥ 200 mg/dl) (%) 19.9 18.5 20.0 18.7 0.512
Hypertension awareness (%) 43.4 41.2 40.4 40.6 0.253
Treatment history for hypertension (%) 26.0 22.6 22.8 24.3 0.100
Mean SBP, mmHg 136.4 ± 18.1 137.2 ± 17.8 137.4 ± 17.8 139.0 ± 19.1 < 0.001
Mean DBP, mmHg 83.6 ± 9.8 84.0 ± 10.7 84.4 ± 9.6 84.5 ± 11.0 < 0.001
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Table 3  Baseline characteristics 
of  normotensivea study 
population across quartiles of 
salt intake
BP blood pressure, SBP systolic blood pressure, DBP diastolic blood pressure
a BP < 130/80 mmHg and no use of anti-hypertensive medications, and not having history of hypertension
Characteristics Salt intake (g/day) quartiles p value
≤ 7.89 > 7.89–9.47 ≥ > 9.47–11.09 ≥ > 11.09
Total population 2179 2118 2001 1775 –
Mean age, years (SD) 40.2 ± 12.5 41.3 ± 12.3 42.6 ± 12.5 42.4 ± 12.8 < 0.001
Gender (% female) 61.5 58.2 51.9 48.2 < 0.001
Educational level (%)
  Less than high-school graduate 54.4 56.2 57.8 66.0 < 0.001
  High-school graduate 23.4 22.4 24.3 19.7
  Some college or more 22.2 21.4 17.9 14.3
Marital status (% married) 79.4 81.9 85.1 86.4 < 0.001
Local residence (% urban) 71.5 72.1 68.1 64.4 < 0.001
Tobacco use (%)
  Never 77.5 79.7 79.2 78.5 0.701
  Former 6.6 5.6 6.4 6.4
  Current 15.9 14.7 14.4 15.1
Alcohol consumption (%)
  Never drank 91.4 91.7 91.5 91.3 0.570
  Former drinker 4.1 4.8 4.6 4.5
  Current drinker 4.5 3.5 3.9 4.2
Fruits intake* (%)
  No intake 20.9 18.9 20.5 21.8 0.503
  < 1 serving 20.7 21.5 20.7 18.3
  1 serving 38.8 40.7 40.1 42.1
  2 serving 13.7 13.8 13.6 13.1
  > 2 serving 5.9 5.1 5.1 4.7
Vegetables intake* (%)
  No intake 32.5 29.6 30.4 32.6 0.081
  < 3 serving 24.8 28.0 24.3 25.8
  3 serving 33.9 33.5 36.4 34.3
  4–5 serving 6.5 7.6 7.1 5.9
  > 5 serving 2.3 1.3 1.8 1.4
Weight status, no./total no. (%)
  Underweight 7.5 4.6 4.0 2.4 < 0.001
  Normal 46.0 41.5 38.4 33.3
  Overweight 33.6 36.6 38.1 39.5
  Obese 12.9 17.3 19.5 24.8
Low activity (%) 55.8 58.3 54.1 52.0 0.014
Wealth index (%)
 Poorest 17.7 17.1 18.4 21.0 0.269
  Poor 19.1 19.5 18.0 19.6
  Moderate 20.5 21.7 21.6 21.6
  Rich 20.8 20.4 21.4 19.5
  Richest 21.9 21.3 20.6 18.3
Diabetes (%) 4.4 4.9 4.8 6.9 0.044
Total cholesterol (≥ 200 mg/dl) (%) 11.1 12.4 10.3 9.8 0.178
Mean SBP, mmHg 112.0 ± 8.9 112.7 ± 8.9 113.5 ± 8.8 114.3 ± 8.8 < 0.001
Mean DBP, mmHg 69.3 ± 6.7 69.7 ± 6.6 69.9 ± 6.5 70.3 ± 6.6 < 0.001
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present study, we did not find a significant association 
between salt intake and DBP. Therefore, if they calculated 
the odds ratio of salt intake and systolic and diastolic BP 
autonomously, they might find an association between salt 
intake and SBP or DBP. The second differences could be 
related to the confounder factors that were used in Sharma 
and colleagues’ study and the present study to find the asso-
ciation between salt intake and BP.
This study had several strengths. First, this study was per-
formed at the national level and the data were representa-
tive sample of Iranian population. Second, the association 
of salt intake was assessed with two classifications of HTN. 
Third, the relationship between salt intake and BP was 
assessed after adjusting for confounders that could affect BP, 
including age, sex, educational level, marital status, local 
residence, tobacco use, alcohol consumption, fruit intake, 
vegetable intake, weight status, low activity, wealth index, 
province, diabetes, total cholesterol, hypertension awareness 
(exclusively for hypertensive individuals), treatment history 
for hypertension (exclusively for hypertensive individuals), 
and interaction between salt intake, total cholesterol, and 
educational level.
Limitations worth mentioning are the cross-sectional 
design of the study, which does not allow for causality and 
method of salt intake measurement. Salt intake was meas-
ured by spot urine sample and salt intake estimation formu-
las, though the gold standard for assessing the salt intake is a 
measurement of 24 h urinary excretion of sodium. However, 
Table 4  Unadjusted and 
adjusted relationship of salt 
intake with SBP and DBP in 
hypertensive and normotensive 
participants
Model 1: adjusted for age, sex, educational level, marital status, and local residence. Model 2: adjusted 
for age, sex, educational level, marital status, local residence, tobacco use, and alcohol consumption, fruit 
intake, vegetable intake. Model 3: adjusted for age, sex, educational level, marital status, local residence, 
tobacco use and alcohol consumption, fruit intake, vegetable intake, weight status, low activity, wealth 
index ,and province. Model 4: adjusted for age, sex, educational level, marital status, local residence, 
tobacco use, alcohol consumption, fruit intake, vegetable intake, weight status, low activity, wealth index, 
province, diabetes, total cholesterol, hypertension awareness (exclusively for hypertensive individuals), 
treatment history for hypertension (exclusively for hypertensive individuals)
SBP systolic blood pressure, DBP diastolic blood pressure, g/day gram per day
a BP ≥ 130/80 mmHg or use of anti-hypertensive medications or self-report of hypertension
b BP ≥ 140/90 mmHg or use of anti-hypertensive medications or self-report of hypertension
c BP < 130/80 mmHg and no use of anti-hypertensive medications and not having history of hypertension
d BP < 140/90 mmHg and no use of anti-hypertensive medications and not having history of hypertension
SBP DBP
β 95% CI p value β 95% CI p value
(A) Hypertensive subjects
 ≥ 130/80a (mmHg) Unadjusted 0.43 (0.25, 0.60) < 0.001 0.15 (0.05, 0.25) 0.002
Adjusted (model 1) 0.34 (0.17, 0.51) < 0.001 0.11 (0.01, 0.20) 0.027
Adjusted (model 2) 0.37 (0.20, 0.54) < 0.001 0.11 (0.01, 0.20) 0.032
Adjusted (model 3) 0.30 (0.11, 0.49) 0.002 0.05 (− 0.05, 0.16) 0.333
Adjusted (model 4) 0.37 (0.18, 0.56) < 0.001 0.07 (− 0.05, 0.18) 0.256
 ≥ 140/90b (mmHg) Unadjusted 0.54 (0.31, 0.78) < 0.001 0.26 (0.12, 0.40) < 0.001
Adjusted (model 1) 0.51 (0.28, 0.74) < 0.001 0.22 (0.08, 0.36) 0.002
Adjusted (model 2) 0.53 (0.29, 0.76) < 0.001 0.21 (0.07, 0.36) 0.003
Adjusted (model 3) 0.48 (0.23, 0.74) < 0.001 0.16 (0.01, 0.31) 0.042
Adjusted (model 4) 0.47 (0.21, 0.74) < 0.001 0.15 (− 0.01, 0.31) 0.068
(B) Normotensive subjects
  < 130/80c (mmHg) Unadjusted 0.41 (0.31, 0.50) < 0.001 0.17 (0.10, 0.24) < 0.001
Adjusted (model 1) 0.35 (0.25, 0.45) < 0.001 0.14 (0.07, 0.22) < 0.001
Adjusted (model 2) 0.32 (0.22, 0.42) < 0.001 0.13 (0.05, 0.20) 0.001
Adjusted (model 3) 0.24 (0.13, 0.35) < 0.001 0.04 (− 0.04, 0.12) 0.320
Adjusted (model 4) 0.26 (0.15, 0.37) < 0.001 0.05 (− 0.03, 0.13) 0.212
 < 140/90d (mmHg) Unadjusted 0.49 (0.40, 0.59) < 0.001 0.23 (0.16, 0.31) < 0.001
Adjusted (model 1) 0.40 (0.31, 0.50) < 0.001 0.19 (0.11, 0.26) < 0.001
Adjusted (model 2) 0.38 (0.29, 0.48) < 0.001 0.17 (0.09, 0.24) < 0.001
Adjusted (model 3) 0.27 (0.17, 0.38) < 0.001 0.06 (− 0.02, 0.14) 0.124
Adjusted (model 4) 0.29 (0.18, 0.39) < 0.001 0.07 (− 0.01, 0.16) 0.078
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in the large-scale studies, measurement of 24 h urinary 
sodium is not cost benefit and it could have a negative effect 
on the collaboration of the participants [20]. According to 
the World Health Organization “The SHAKE Technical 
Package for Salt Reduction”, spot urine sodium can be con-
sidered as an useful alternative to 24 h urine sodium for 
estimating the mean population salt intake in the countries 
that lack the resources or capacity to do 24 h urine collection 
properly [21].
For reducing population salt intake, several actions, 
including monitoring of population salt intake, identifying 
the main sources of salt in the diet, and designing effec-
tive policies for salt reduction, are needed [22]. According 
to the current survey, the mean salt intake in both hyper-
tensive and normotensive people was greater than the level 
of recommendation by the World Health Organization 
(WHO). These values are in accordance with other coun-
tries. According to the INTERMAP study, in the UK, the 
mean salt intake among normotensive, prehypertensive, 
untreated hypertensive, and treated hypertensive people who 
were not on reduced salt diet were 8 g/day, 8.8 g/day, 8.7 g/
day, and 9 g/day, respectively. In China, the mean salt intake 
Table 5  Unadjusted and adjusted relationship of salt intake with SBP and DBP in hypertensive participants across quartiles of salt intake
Model 1: adjusted for age, sex, educational level, marital status and local residence. Model 2: adjusted for age, sex, educational level, marital 
status, local residence, tobacco use and alcohol consumption, fruit intake, vegetable intake. Model 3: adjusted for age, sex, educational level, 
marital status, local residence, tobacco use and alcohol consumption, fruit intake, vegetable intake, weight status, low activity, wealth index and 
province. Model 4: adjusted for age, sex, educational level, marital status, local residence, tobacco use, alcohol consumption, fruit intake, veg-
etable intake, weight status, low activity, wealth index, province, diabetes, total cholesterol, hypertension awareness (exclusively for hypertensive 
individuals), treatment history for hypertension (exclusively for hypertensive individuals) and interaction between salt intake, total cholesterol 
and educational level
SBP systolic blood pressure, DBP diastolic blood pressure, g/day gram per day
a BP ≥ 130/80 mmHg or use of anti-hypertensive medications or self-report of hypertension
b BP ≥ 140/90 mmHg or use of anti-hypertensive medications or self-report of hypertension
*p < 0.1; **p < 0.05
Salt intake (g/day) quartiles p for trend
≤ 7.89 > 7.89–9.47 ≥ > 9.47–11.09 ≥ > 11.09
≥ 130/80a (mmHg)
 SBP
    Unadjusted Ref 0.87 (− 0.33, 2.06) 1.08 (− 0.14, 2.29)* 2.64 (1.43, 3.85)** < 0.001
    Adjusted (model 1) Ref 0.74 (− 0.37, 1.86) 0.77 (− 0.36, 1.91) 2.17 (1.01, 3.33)** < 0.001
    Adjusted (model 2) Ref 0.78 (− 0.34, 1.90) 0.85 (− 0.31, 2.00) 2.26 (1.09, 3.43)** < 0.001
      Adjusted (model 3) Ref 0.72 (− 0.47, 1.91) 0.63 (− 0.61, 1.87) 1.92 (0.65, 3.19)** < 0.001
    Adjusted (model 4) Ref 1.15 (− 0.53, 2.82) 1.92 (0.06, 3.79)** 3.81 (2.00, 5.61)** < 0.001
 DBP
    Unadjusted Ref 0.36 (− 0.31, 1.04) 0.75 (0.13, 1.36)** 0.84 (0.18, 1.49)** < 0.001
      Adjusted (model 1) Ref 0.25 (− 0.44, 0.93) 0.58 (− 0.04, 1.21)* 0.53 (− 0.12, 1.18) < 0.001
    Adjusted (model 2) Ref 0.23 (− 0.46, 0.92) 0.55 (− 0.08, 1.18)* 0.52 (− 0.14, 1.18) 0.002
    Adjusted (model 3) Ref 0.13 (− 0.59, 0.85) 0.30 (− 0.38, 0.97) 0.20 (− 0.53, 0.92) 0.162
    Adjusted (model 4) Ref 0.18 (− 0.83, 1.18) 0.55 (− 0.42, 1.53) 1.18 (0.16, 2.20)** 0.252
≥ 140/90b (mmHg)
 SBP
    Unadjusted Ref 1.17 (− 0.42, 2.76) 1.62 (− 0.01, 3.26)* 3.28 (1.66, 4.89)** < 0.001
    Adjusted (model 1) Ref 1.23 (− 0.33, 2.79) 1.44 (− 0.16, 3.05)* 3.09 (1.47, 4.71)** < 0.001
      Adjusted (model 2) Ref 1.23 (− 0.32, 2.79) 1.50 (− 0.12, 3.11)* 3.15 (1.53, 4.78)** < 0.001
      Adjusted (model 3) Ref 1.19 (− 0.44, 2.82) 1.27 (− 0.45, 2.99) 3.11 (1.36, 4.86)** < 0.001
    Adjusted (model 4) Ref 1.23 (− 1.00, 3.45) 2.15 (− 0.47, 4.76) 4.42 (1.95, 6.89)** < 0.001
 DBP
    Unadjusted Ref 0.77 (− 0.25, 1.79) 1.23 (0.30, 2.15)** 1.60 (0.63, 2.58)** < 0.001
    Adjusted (model 1) Ref 0.59 (− 0.45, 1.62) 1.10 (0.16, 2.04)** 1.24 (0.27, 2.21)** < 0.001
    Adjusted (model 2) Ref 0.55 (− 0.48, 1.58) 1.04 (0.10, 1.98)** 1.20 (0.23, 2.18)** < 0.001
    Adjusted (model 3) Ref 0.38 (− 0.67, 1.43) 0.74 (− 0.25, 1.73) 0.91 (− 0.15, 1.96)* 0.009
    Adjusted (model 4) Ref 0.25 (− 1.19, 1.69) 0.89 (− 0.53, 2.31) 1.65 (0.18, 3.13)** 0.058
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in normotensive people was 12.7 g/day, in prehypertensive 
people was 13.6 g/day, in untreated hypertensive people was 
14.5 g/day, and in treated hypertensive people was 15.5 g/
day. The mean salt intake among Japanese normotensive, 
prehypertensive, untreated hypertensive, and treated hyper-
tensive people was 11.3 g/day, 12.2 g/day, 12.2 g/day, and 
11.6 g/day, respectively. In the USA, the mean salt intake 
among normotensive, prehypertensive, untreated hyperten-
sive, and treated hypertensive people was 9 g/day, 10 g/day, 
9.8 g/day and 10.3 g/day, respectively [23].
In Iran, the main sources of salt intake are bread, cheese, 
and yogurt drinks [24]. Bread is one of the main sources of 
salt intake in other countries such as Germany, as well [25]. 
In European countries, the main sources of salt intake are 
Fig. 1  Forest plot of changes in SBP and DBP of each salt quartile in comparison to the first quartile. Data are based on multivariable linear 
regression models in survey analysis with adjustment for other studied covariates
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processed foods, bread, meat, and cheese [25, 26]. In the 
East Asian countries such as Japan, South Korea, and China, 
one of the main dietary sources of salt is soy sauce that is 
used as a seasoning in their foods [26, 27].
To date, several policies have been proposed to reduce 
the salt intake of populations to the level recommended by 
WHO or other organizations. Some of these policies have 
been executed at the population level such as reformula-
tion of the foods, taxation, food labeling, public health cam-
paigns, creating an enabling environment for salt reduction 
through promotion of healthy food in workplace or school, or 
advertising controls and some of them have been performed 
at the individual level such as dietary counseling [26, 28, 
29]. The finding of the previous studies sheds light that salt 
restriction strategies had a different effect on BP in hyper-
tensive and normotensive people [28, 29]. It was revealed 
that the magnitude of salt restriction effect on BP is higher in 
hypertensive people than that in normotensive people [4, 9]. 
Furthermore, there is a debate that how much salt reduction 
is acceptable in the general population. Some of the studies 
reported that there is a U-shaped association between salt 
intake and BP that both excess salt intake and severe salt 
restriction could increase the risk of CVDs [30]. Therefore, 
policymakers should consider this gap of evidence in the 
Table 6  Unadjusted and adjusted relationship of salt intake to SBP and DBP in normotensive participants across quartiles of salt intake
Model 1: adjusted for age, sex, educational level, marital status and local residence. Model 2: adjusted for age, sex, educational level, marital 
status, local residence, tobacco use and alcohol consumption, fruit intake, vegetable intake. Model 3: adjusted for age, sex, educational level, 
marital status, local residence, tobacco use and alcohol consumption, fruit intake, vegetable intake, weight status, low activity, wealth index and 
province. Model 4: adjusted for age, sex, educational level, marital status, local residence, tobacco use, alcohol consumption, fruit intake, vegeta-
ble intake, weight status, low activity, wealth index, province, diabetes, total cholesterol and interaction between salt intake, total cholesterol and 
educational level
SBP systolic blood pressure, DBP diastolic blood pressure, g/day gram per day
a BP < 130/80 mmHg and no use of anti-hypertensive medications and not having history of hypertension
b BP < 140/90 mmHg and no use of anti-hypertensive medications and not having history of hypertension
*p < 0.1; **p < 0.05
Salt intake (g/day) quartiles p for trend
≤ 7.89 > 7.89–9.47 ≥ > 9.47–11.09 ≥ > 11.09
<130/80a (mmHg)
 SBP
      Unadjusted Ref 0.70 (0.08, 1.33)** 1.55 (0.91, 2.18)** 2.31 (1.67, 2.94)** < 0.001
      Adjusted (model 1) Ref 0.61 (− 0.01, 1.22)* 1.26 (0.62, 1.90)** 1.93 (1.28, 2.57)** < 0.001
    Adjusted (model 2) Ref 0.54 (− 0.07, 1.15)* 1.14 (0.50, 1.79)** 1.78 (1.13, 2.43)** < 0.001
    Adjusted (model 3) Ref 0.45 (− 0.16, 1.06) 1.06 (0.39, 1.73)** 1.16 (0.45, 1.87)** 0.003
    Adjusted (model 4) Ref 0.48 (− 0.36, 1.32) 0.66 (− 0.24, 1.56) 1.39 (0.52, 2.26)** 0.002
 DBP
      Unadjusted Ref 0.48 (0.03, 0.94)** 0.59 (0.12, 1.06)** 1.00 (0.53, 1.48)** < 0.001
    Adjusted (model 1) Ref 0.43 (− 0.01, 0.88)* 0.43 (− 0.04, 0.90)* 0.85 (0.37, 1.33)** < 0.001
    Adjusted (model 2) Ref 0.37 (− 0.07, 0.82) 0.36 (− 0.11, 0.83) 0.74 (0.26, 1.22)** 0.002
    Adjusted (model 3) Ref 0.12 (− 0.34, 0.58) 0.10 (− 0.40, 0.60) 0.15 (− 0.37, 0.67) 0.315
    Adjusted (model 4) Ref 0.49 (− 0.17, 1.16) 0.05 (− 0.63, 0.73) 0.57 (− 0.12, 1.25) 0.230
< 140/90b (mmHg)
 SBP
    Unadjusted Ref 1.03 (0.39, 1.67)** 1.89 (1.26, 2.52)** 3.02 (2.41, 3.63)** < 0.001
    Adjusted (model 1) Ref 0.82 (0.20, 1.44)** 1.44 (0.81, 2.08)** 2.39 (1.78, 3.00)** < 0.001
    Adjusted (model 2) Ref 0.75 (0.14, 1.36)** 1.32 (0.69, 1.95)** 2.23 (1.62, 2.83)** < 0.001
    Adjusted (model 3) Ref 0.60 (− 0.03, 1.23)* 1.17 (0.50, 1.84)** 1.6 (0.93, 2.26)** < 0.001
    Adjusted (model 4) Ref 0.63 (− 0.26, 1.54) 1.10 (0.16, 2.04)** 1.76 (0.90, 2.62)** < 0.001
 DBP
      Unadjusted Ref 0.53 (0.05, 1.01)** 0.96 (0.48, 1.44)** 1.40 (0.92, 1.88)** < 0.001
    Adjusted (model 1) Ref 0.40 (− 0.07, 0.87)* 0.67 (0.19, 1.15)** 1.05 (0.57, 1.54)** < 0.001
    Adjusted (model 2) Ref 0.33 (− 0.14, 0.80) 0.58 (0.11, 1.06)** 0.94 (0.46, 1.42)** < 0.001
    Adjusted (model 3) Ref 0.08 (− 0.40, 0.56) 0.28 (− 0.23, 0.78) 0.35 (− 0.17, 0.88) 0.407
      Adjusted (model 4) Ref 0.35 (− 0.34, 1.03) 0.30 (− 0.40, 1.00) 0.72 (0.02, 1.42)** 0.372
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salt reduction policies. Moreover, it is suggested that future 
studies investigate that how much reduction in salt intake 
is safe and could reduce the risk of CVDs and promote the 
health status of the general population [30].
Conclusion
In conclusion, there was a strong association between salt 
intake and SBP in hypertensive people. In normotensive 
people, there was a significant association between salt 
intake and SBP, but not as strong as that in hypertensive 
people. Based on the findings of the present study and the 
current evidence, hypertensive people may obtain more ben-
efit from salt restriction policies.
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